Trial
NCT00539838
A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Genentech, Inc.
Collaborators
Roche Pharma AG
Condition
Systemic Lupus Erythematosus
Intervention
Prednisone
Why stopped
The study was terminated prematurely when the decision was made that ocrelizumab was not likely to benefit this patient population.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-09-17